Financings in Brief: Sight Resource
This article was originally published in The Gray Sheet
Executive Summary
Sight Resource: Laser vision correction center company, formerly NewVision Technology, nets about $6.1 mil. from the exercise of "more than 99%" of warrants issued in conjunction with a March 1993 initial public offering. The warrants were exercised in conjunction with the Oct. 20 FDA approval of Summit Technology's excimer laser for photorefractive keratectomy ("The Gray Sheet" Oct. 30, p. 4). Sight Resource states that 13 of its lasers are being upgraded for PRK use and it will begin treating patients at its Boston facility on Dec. 15; seven out of 28 Sight Resource centers are expected to be offering PRK by year end...
You may also be interested in...
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.